Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
the FCPA is one of those things that needs to go and will probably eventually be ruled unconstitutional if not repealed
It's stood the test of time, unfortunately - 40 years, believe it or not.
It was not a portend of bad news, thass fer sure
Do you know if any of those were directors' fees issued in lieu of cash?
has a (surprisingly high) 9% discount to the closing price on Wednesday
Agreed, and calls into question company's commitment to shareholders
CAMBRIDGE, Mass., March 16, 2017 (GLOBE NEWSWIRE) -- Editas Medicine, Inc. (EDIT), a leading genome editing company, today announced the pricing of an underwritten offering of 4,000,000 shares of its common stock at a price to the public of $22.50 per share. The gross proceeds to Editas Medicine from this offering are expected to be approximately $90 million, before deducting underwriting discounts and commissions and other estimated offering expenses. Editas Medicine has granted the underwriters a 30-day option to purchase up to an additional 600,000 shares of common stock on the same terms and conditions.
Editas Medicine intends to use the net proceeds of the offering to fund preclinical studies and clinical trials for its LCA10 program and its other programs to treat genetic and infectious diseases of the eye, preclinical studies of its programs to treat non-malignant hematologic diseases, preclinical studies in its collaboration with Juno Therapeutics, preclinical studies of other research programs, continued expansion of its platform technology, and for working capital and other general corporate purposes.
Much of the rest of the world gets along happily with single payer systems, with no obvious decline in treatment quality or (especially) outcome, or patient satisfaction.
Mayo's estimate for an aortic valve replacement was $90k. Bill to be presented to Medicare of course.
I had a preliminary catheter procedure (sedation only, go home same day). There were 8 R.N.'s assisting in the preop.
Seems like a lot.
standard ad hominem response - impugn motives
Would be very interested in your view of the likelihood of a UC Berkeley appeal in the CRISPR patent case.
Neither side seems to be considering compromise
Thank you
How does FGEN fit in that set of criteria?
Remember you're due a last cigarette
Unnecessary procedures would get my vote. (I'm a patient at Mayo Florida)
I assume the EXEL move is ARIA related?
Damn. Taxes
Not many expected the black label on pona either
Not enough volume for shorts to cover. IMO
That's why they call it a short squeeze
Most traded I presume
http://www.telegraph.co.uk/investing/shares/shares-did-investors-buy-2016-did-perform/
Investors profited from the falls in markets immediately after the Brexit vote, with opportunistic purchases after the EU referendum dominating the share buying for the year.
Telegraph Money has compiled the most bought shares in 2016 from the leading online platforms.
We collected information from Hargreaves Lansdown, AJ Bell, Barclays Direct, Interactive Investors and the Share Centre, tracking the shares that appeared most frequently across the providers' top bought lists.
AJ Bell said that investors were more active than ever before, with the platform reaching record trading volumes in the year. The number of trades carried out since the EU referendum in June was 55pc higher than the same period last year.
TELEGRAPH
The 15 most bought shares in 2016
Aviva
Barclays
BP
easyJet
GlaxoSmithKline
Glencore
HSBC
ITV
Legal & General Group
Lloyds Banking Group
National Grid
Royal Dutch Shell
Sirius Minerals
Taylor Wimpey
Vodafone
FT snippet
A US drugmaker has put a price tag of more than $800 on a pinworm treatment — 200 times more expensive than the equivalent medicine on British pharmacy shelves, in the latest example of “price gouging” in the world’s largest healthcare market.
Impax Laboratories started selling mebendazole this year at an average wholesale price of $442 per pill, according to figures seen by the Financial Times, which were checked with several US pharmacy chains including Walgreens and CVS.
Most cases of pinworm, a parasitic infection also known as threadworm, require two pills, meaning a course of treatment costs about $884. The drug is available prescription-only in the US but can be bought over the counter in the UK, where Boots, a British chemist chain, charges £6.99 for a pack of four pills, or £1.75 each.
Pattern day trader not a problem, or maybe you already are one?
stupidest assertion of the day, re Tillerson's experience
The long time oil executive does not have any diplomatic experience.....
!!!!!!!!!!
In June he didn't know he would become president
This news hasn't yet been referenced here I think
The CMA has fined pharma companies Pfizer and Flynn Pharma nearly £90 million for charging excessive prices to the NHS for an anti-epilepsy drug.
The Competition and Markets Authority (CMA) has imposed a record £84.2 million fine on the pharmaceutical manufacturer Pfizer, and a £5.2 million fine on the distributor Flynn Pharma after finding that each broke competition law by charging excessive and unfair prices in the UK for phenytoin sodium capsules, an anti-epilepsy drug. The CMA has also ordered the companies to reduce their prices.
The fines follow prices increasing by up to 2,600% overnight after the drug was deliberately de-branded in September 2012. For example, the amount the NHS was charged for 100mg packs of the drug rocketed from £2.83 to £67.50, before reducing to £54.00 from May 2014. As a result of the price increases, NHS expenditure on phenytoin sodium capsules increased from about £2 million a year in 2012 to about £50 million in 2013. The prices of the drug in the UK have also been many times higher than Pfizer’s prices for the same drug in any other European country.
China could indeed be the flash point
Telegraph:
Donald Trump launched an attack against China last night, accusing Beijing of currency manipulation and flexing its military might in the South China Sea.
The tweets deepened a brewing diplomatic row that began on Friday when the US president-elect broke decades of US policy and spoke on the telephone with President Tsai Ing-wen of Taiwan.
That would be another surprise. Trump paints with a broad brush. NYT is almost ecstatic over the Mattis appointment, Bannon not so much
None of these was a 10b5-1 transaction.
Malice aforethought, in other words.
We (Ariad) couldn't be in better hands!!!
gèrénchóngbài, wouldn't you agree?
should be, yes
What would the market cap be at $90 per share? I can't count that high
FWIW, Merrill has removed LLY from its US 1 list.
In what form might one take B 12?
Thanks Peter
Has there been any recent leakage from the Trump camp that might give us a fix whether repatriation remains a priority? It would use up political capital that Trump might want to keep in reserve.
Mr Scaramucci, a member of Mr Trump’s economic advisory council, said the president-elect would finance the new spending plan with “historically cheap debt and public-private partnerships” and insisted it would reduce deficits by stimulating economic growth.
What a Laffer.
There were a few fleas on that dog IMO
They'd be smart to not price the drug and let the buyers of the company do that
Can you identify those buyers?
Should it not be an accreting asset with the passage of time as we get closer to the merger?
MON
A cursory glance at the chart tells me the market's prognosis is not good - but I still own a few shares.
That's a meaningful answer that I did not expect <another G>
Would you sell anything to buy TRIL? <G>